Eurofins Reinforces Its Pharmaceutical Quality Control Capability with the Acquisition of IDmyk
January 16 2014 - 12:30AM
Business Wire
Regulatory news:
Eurofins Scientific (Paris:ERF) (EUFI.PA), the global leader in
bio-analytical testing, announces the acquisition of IDmyk, a
leading laboratory specialized in the areas of detection,
identification and molecular typing of microorganisms for the
pharmaceutical industry. The acquisition reinforces Eurofins’
pharmaceutical quality control (QC) offering, and complements its
existing capabilities in microbiological analysis.
Since 2000, IDmyk has developed market-leading expertise in
establishing the genetic identity of microorganisms to support
product or process-related investigations. As such, IDmyk has the
largest validated proprietary database for Good Manufacturing
Practice (GMP) identification service in the industry. These,
combined with Eurofins’ existing identification capabilities,
strengthen the Group’s pharmaceutical QC service offering.
Furthermore, rolling-out the methods to the relevant laboratories
across the Group network will allow Eurofins to benefit from
reduced costs given the use of proprietary reagents in the
processes.
IDmyk, based in Lyon, France, with revenues of less than EUR 2m
currently, will benefit from Eurofins’ focus on innovation, with
substantial resources for research and development. For example, as
one of the global leaders in genomics services, Eurofins has
considerable expertise in the area of next-generation sequencing,
which may be used for faster, more precise identification of
organisms at the strain level. In addition, IDmyk will have access
to Eurofins’ wide portfolio of products and services, as well as
access to the Group’s clients.
Notes for the editor:Eurofins – a global leader in
bio-analysisEurofins Scientific is the world leader in food and
pharmaceutical products testing. It is also number one in the world
in the field of environmental laboratory services and one of the
global market leaders in agroscience, genomics and central
laboratory services.
With over 15,000 staff in more than 190 laboratories across 37
countries, Eurofins offers a portfolio of over 100,000 reliable
analytical methods for evaluating the safety, identity,
composition, authenticity, origin and purity of biological
substances and products. The Group provides its customers with
high-quality services, accurate results on time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the NYSE
Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA,
Bloomberg ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the data
available to the Company as of the date of publication, but no
guarantee can be made as to their validity.
Dr. Gautier Decock, Phone: +33 1 69 10 88 80Eurofins
Pharma Quality ControlE-mail: gautierdecock@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Sep 2023 to Sep 2024